

## Study: ENGOT-ov85 / MK-2870-021

Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy

### MaNGO Sites:

Prov	City	Site	Principal Investigator	Active
BS	Brescia	Spedali Civili	Germana Tognon *	
LC	Lecco	Ospedale Manzoni-	Federica Villa	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	Yes
MI	Milano	Istituto Nazionale dei Tumori	Mara Mantiero	
MO	Modena	AOU Policlinico	Roberto Sabbatini	
PD	Padova	Istituto Oncologico Veneto	Valentina Guarneri	
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero	
RM	Roma	Fondazione Policlinico Gemelli IRCCS	Anna Fagotti	MITO site managed by MaNGO

\* **MaNGO Principal Investigator**